4-甲氧基苯脲 | 1566-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲氧基苯脲
• 中文别名: (4-甲氧苯基)尿素
• 英文名称: p-anisidine urea
• 英文别名: 1-(4-methoxyphenyl)urea；4-Methoxyphenylurea；(4-methoxyphenyl)urea
• CAS: 1566-42-3
• 化学式: C₈H₁₀N₂O₂
• mdl: MFCD00014789
• 分子量: 166.18
• InChiKey: PGUKYDVWVXRPKK-UHFFFAOYSA-N

物化性质

• 熔点：
  164-165°C
• 沸点：
  284.7±23.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)
• 溶解度：
  微溶于在甲醇中
• 最大波长(λmax)：
  289nm(EtOH)(lit.)
• 稳定性/保质期：

  在常温常压下稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2924299090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-METHOXYPHENYLUREA
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 1566-42-3
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C8H10N2O2
Molecular Weight : 166,18 g/mol
CAS-No. : 1566-42-3
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-METHOXYPHENYLUREA
Acute Tox. 4; H302 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 0,887
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: YT6451200
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲氧基苯脲 在 吡啶 、 四丁基碘化铵 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.33h， 生成 N-(p-methoxyphenyl)-N-(1,2-propdienyl)cyanamide
  参考文献：
  名称：

  N-烯丙基氰胺的合成与反应性

  摘要：

  使用炔丙醇和N-氰基-N-苯基-对甲基苯磺酰胺，通过一锅脱氧氰酰胺化-异构化方法获得了N-烯基氰胺。通过衍生化，使用氢化芳基化，加氢胺化和环加成方法来获得一系列氰胺产品，探索了这类新型烯丙酰胺的实用性，而使用现有方法很难获得这些产品。

  DOI：

  10.1021/acs.orglett.8b02225
• 作为产物：
  描述：

  4-甲氧基苯甲酰胺 在 碘苯二乙酸 、 氨 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以99%的产率得到4-甲氧基苯脲
  参考文献：
  名称：

  由伯酰胺直接合成N取代的尿素

  摘要：

  通过在甲醇中的氨源（NH 3或氨基甲酸铵）存在下用苯乙酸二乙酸酯（PIDA）处理伯酰胺，可以实现一种直接，方便的制备N-取代脲的方法。使用2,2,2-三氟乙醇（TFE）作为溶剂可提高高价碘物种的亲电子性，并允许合成贫电子羧酰胺。该转化涉及通过起始酰胺的霍夫曼重排在原位产生的异氰酸酯中间体上亲核加成氨。

  DOI：

  10.1055/s-0040-1707103
• 作为试剂：
  描述：

  反式肉桂醛 、 4-碘苯甲醚 在 4-甲氧基苯脲 、 palladium diacetate 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以44.444%的产率得到
  参考文献：
  名称：

  Selective reactivity of electron-rich aryl iodides in the Heck arylation of disubstituted alkenes catalyzed by palladium–arylurea complexes

  摘要：

  A catalyst consisting of 1 mol % of the 1:2 complex of Pd(OAc)(2) with N-(4-carbethoxyphenyl)urea promotes the Heck arylation of 2- or 3-substituted, conjugated esters, nitriles, aldehydes, and ketones (an uncharacteristically broad range of substrates), but only with electron-rich aryl iodides (an uncharacteristically narrow range of halides). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.09.019

文献信息

• [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2019243550A1

  公开（公告）日：2019-12-26

  Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

  提供了公式（I）的噻吩衍生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途，如过敏、1型超敏反应或家族性鼻窦炎。
• [EN] PYRROLOPYRIMIDINES<br/>[FR] PYRROLOPYRIMIDINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009016132A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及化合物或其药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及一类极化样激酶（PLKs）抑制剂化合物，用于治疗由PLK介导的疾病状态，特别是PLK4，特别是在治疗涉及异常细胞增殖的病理过程中有用的化合物，如肿瘤生长、类风湿性关节炎、再狭窄和动脉粥样硬化。
• Design, synthesis, and biological evaluation of hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents
  作者：Mao Zhang、Yu-Ru Liang、Huan Li、Ming-Ming Liu、Yang Wang

  DOI：10.1016/j.bmc.2017.10.045

  日期：2017.12

  hydantoin-bridged analogues of combretastatin A-4 (CA-4) were designed, synthesized and evaluated for antiproliferative activities in vitro and in vivo. The most potent compound 8d, showed potent cytotoxicity against four human cancer cell lines with IC50 values of 0.186–0.279 μM, and possessed the efficacy of inhibiting tubulin polymerization, disrupting in vitro vascularization, blocking cell cycle in G2/M phase

  设计，合成并评估了康布雷他汀A-4（CA-4）的一系列新的乙内酰脲桥联类似物在体外和体内的抗增殖活性。最强效的化合物8d对4种人类癌细胞系表现出强大的细胞毒性，IC 50值为0.186–0.279μM，并具有抑制微管蛋白聚合，破坏体外血管形成，阻断G 2 / M期细胞周期并诱导细胞凋亡的功效。细胞凋亡。在裸鼠异种移植模型中，8d显着抑制肿瘤生长并显示出低毒性。进一步的手性分离证明（R）-（-）- 8d它们是IC 50值为0.081-0.157 M的优先对映体。这些结果表明，乙内酰脲衍生物作为抑制微管蛋白聚合的潜在抗癌剂值得进一步研究。
• Catalytic hydration of cyanamides with phosphinous acid-based ruthenium(<scp>ii</scp>) and osmium(<scp>ii</scp>) complexes: scope and mechanistic insights
  作者：Rebeca González-Fernández、Daniel Álvarez、Pascale Crochet、Victorio Cadierno、M. Isabel Menéndez、Ramón López

  DOI：10.1039/d0cy00523a

  日期：——

  phosphinous acid-based complexes [MCl2(η6-p-cymene)(PMe2OH)] (M = Ru (1), Os (2)) as catalysts. The reactions proceeded cleanly under mild conditions (40–70 °C), in the absence of any additive, employing low metal loadings (1 mol%) and water as the sole solvent. In almost all the cases, the osmium complex 2 featured a superior reactivity in comparison to that of its ruthenium counterpart 1. In addition

  通过使用水合相应的氰胺R 1 R 2 NC N成功地完成了多种脲R 1 R 2 NC（O）NH 2的合成（R 1和R 2 =烷基，芳基或H； 26个实例）的三价膦酸基配合物[的MC1 2（η 6 - p -cymene）（PME 2 OH）]（M =茹（1），锇（2））作为催化剂。反应在温和的条件下（40-70°C）干净进行，没有任何添加剂，使用低金属负载量（1 mol％）和水作为唯一溶剂。在几乎所有情况下，complex配合物2的反应活性都比钌配合物1高。另外，对于两种催化剂，氰酰胺底物水合所观察到的反应速率明显快于涉及传统脂族和芳族腈的反应速率。计算研究使我们能够合理化所有这些趋势。因此，计算表明存在直接与碳原子相连的氮原子当与金属中心配位时，N键通过感应效应使腈碳电子减少，从而促进次膦酸配体的OH基团对该碳的分子内亲核攻击。另一方面，Os对Ru的较高反应性似乎与初始金属环上较低的环应
• Dimethylformamide Catalyzed Synthesis of Novel Heterocycles-Their Characterization and Antimicrobial Evaluation
  作者：Vijay V. Dabholkar、Sunil R. Patil、Rajesh V. Pandey

  DOI：10.1002/jhet.1073

  日期：2013.3

  Indandione 1 was brominated to yield 2‐bromoIndandione 2, which further reacted with substituted thiocarbamides, carbamides, 2‐aminothiophenols, 2‐aminophenol, and triazole to furnished 3‐substituted aniline‐2‐thia‐4‐aza‐6,7‐benzo‐8‐oxo‐bicyclo[3.3.0]‐1(5),3‐octadiene 3, 3‐substituted aniline‐2‐oxa‐4‐aza‐6,7‐benzo‐8‐oxo‐bicyclo[3.3.0]‐1(5),3‐octadiene 4, 2‐Thia‐5‐aza‐9‐oxo‐3,4‐(3′‐substituted) benzo‐7

  茚满二酮1溴化生成2-溴茚满二酮2，后者进一步与取代的硫代氨基甲酸酯，脲，2-氨基硫酚，2-氨基苯酚和三唑反应生成3取代的苯胺-2-二硫杂-4-氮杂-6,7-苯并呋喃。 -8-氧代双环[3.3.0] -1（5），3-辛二烯3，3-取代的苯胺-2-氧杂-4-氮杂-6,7-苯并-8-氧代-双环[3.3.0 ] -1（5），3-辛二烯4，2 -Thia-5-氮杂-9-oxo-3,4-（3'-取代）苯并-7,8-苯并双环[4.3.0] -1 （6）壬烯5，2-氧杂-5-氮杂-9-氧代（3,4） - （7,8） -二苯并-二环[4.3.0] -1（6）壬烯6，3'-取代-（1'，2'，4'）triazolo [5,6-b] [indeno（2,3-e）]-1,3,4-噻二嗪7， 分别。根据光谱技术阐明了化合物的结构，进一步筛选了具有代表性的化合物的抗菌活性。